Streetbeat News

Revenues

SPY

USA Retail Sales for January decreased by 0.8%, which is lower than the estimated -0.2% and the previous month's 0.4%.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:30 pm

SPY

Core Retail Sales in January decreased by 0.6%, contrary to the expected increase of 0.2%. This indicates a contraction in consumer spending which could have implications for economic growth and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:30 pm

LTRN

Lantern Pharma is advancing its ADC program for solid tumor cancers, leveraging its RADR® AI platform and a unique conjugation approach. The cryptophycin-based ADC has shown high potency in preclinical tests and is aimed at tumors resistant to current therapies. Lantern plans to move towards IND development in 2024, targeting a market expected to generate over $24 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:07 pm

ITGR

Integer Holdings projects its full-year 2024 sales to be between $1.735 billion and $1.77 billion, with an adjusted EPS of $5.43, slightly below the consensus estimates of $1.75 billion in sales and an EPS of $5.45.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:06 pm

FIVN

Eight analysts have recently updated their recommendations for Five9 (NASDAQ:FIVN), showing a mix of bullish and somewhat bullish perspectives with no bearish views. The average 12-month price target is now $91.62, up from $84.40, indicating an 8.55% increase. Analysts from firms including Needham, Keybanc, Piper Sandler, Deutsche Bank, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, reflecting positive sentiment towards Five9's market position despite its challenges in revenue growth, net margin, ROE, ROA, and debt management compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 1:00 pm

TYL

In the past three months, Tyler Technologies (NYSE:TYL) received varied analyst ratings, with a recent average price target of $486.00, marking a 2.32% increase from the previous target. The company's financial health shows below-average market capitalization, revenue growth, net margin, ROE, and ROA compared to industry peers, but a conservative debt management approach. Analysts' ratings and price targets reflect their views on the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 1:00 pm

KELYA

Kelly Services anticipates growth in Q1 2024 European staffing operations revenue, alongside sustained structural expense reductions and positive outcomes from growth initiatives, to further expand its EBITDA margin.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:39 pm

OGN

Organon forecasts its full year revenues for 2024 to be between $6.2 billion and $6.5 billion, aligning closely with the consensus estimate of $6.40 billion. Additionally, the company anticipates an adjusted EBITDA margin of 31.0% to 33.0%.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:38 pm

RPRX

Royalty Pharma's Q4 sales were $596.00M, missing the analyst consensus estimate of $673.65M by 11.53%. However, net income was $494M, a significant improvement from a loss of $(456)M the previous year. Sales increased by 5.30% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:34 pm

NTLA

Intellia Therapeutics and ReCode Therapeutics have formed a strategic collaboration to develop genomic medicines for treating Cystic Fibrosis (CF), a serious genetic disease. While financial terms were not disclosed, Intellia is set to receive development and commercial milestone payments, along with royalties on potential sales. Intellia also has an option to lead commercialization in the U.S. for certain programs.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:34 pm